Gabapentin Improves Symptoms of Functional Dyspepsia in a Retrospective, Open-label Cohort Study

Staller, Kyle; Thurler, Andrea H.; Reynolds, Justin S.; Dimisko, Laurie; McGovern, Ryan P.; Skarbinski, Kristina; Kuo, Braden

doi:10.1097/mcg.0000000000001034

Cited by 13 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, pregabalin also proved beneficial in reducing IBS‐related abdominal pain, bloating and diarrhoea symptoms 26 . Relevant investigation into the treatment of FD is limited to one small retrospective study which showed that gabapentin was beneficial in improving overall symptoms 27 . There is also no information on how it affects upper gastrointestinal motility.…”

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

Kotikula

Thinrungroj

Pinyopornpanish

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Currently, central neuromodulators are among the therapeutic options for the treatment of functional dyspepsia (FD). Pregabalin, a gabapentinoid, is a neuromodulator that could potentially improve visceral hypersensitivity in FD patients. Aim To assess the efficacy and safety of pregabalin for the treatment of FD Methods We performed a randomised placebo‐controlled study including FD patients who did not respond to proton pump inhibitors. Patients were randomly assigned to receive pregabalin (75 mg daily) or placebo for 8 weeks. The primary outcome was an adequate relief response rate. The secondary outcomes were improvement in quality of life, pain scores in divided categories, and safety profile. Results Of 72 patients enrolled, 34 received pregabalin and 38 received placebo. The self‐reported adequate relief rates in the pregabalin and placebo groups were 70.6% and 42.1% at week 4 (P = 0.02), and 70.6% and 44.7% at week 8 (P = 0.03), respectively. The reduction in global symptoms in the pregabalin and placebo groups were 11.7 ± 10.6 and 3.7 ± 8.9 points at week 4 (P < 0.01) and 15.1 ± 12.2 and 8.0 ± 10.2 points at week 8 (P = 0.01), respectively. Pregabalin improved the overall quality of life (P = 0.03). The most common adverse event with pregabalin was dizziness, occurring in 51.6% of patients. Conclusions Pregabalin led to significant alleviation of dyspeptic symptoms, especially in patients with predominant epigastric pain . Thaiclinicaltrials.org #TCTR20200404002.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

Kotikula

Thinrungroj

Pinyopornpanish

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…21 Studies suggest that low-dose gabapentin may be effective in the treatment of functional dyspepsia and N/V. 22 Pain management is also important as abdominal pain is a frequent symptom in those with chronic N/V. Opioids should be avoided as they can worsen gastric motility and nausea.…”

Section: Pharmacologic Therapiesmentioning

confidence: 99%

A Practical 5-Step Approach to Nausea and Vomiting

Tome

Kamboj

Sweetser

2022

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…Gabapentin led to a significant improvement of dyspeptic symptoms such as abdominal pain and postprandial fullness in a retrospective study [ 85 ]. An RCT on 126 refractory FD patients, either taking omeprazole 20 mg ID plus placebo or omeprazole 20 mg ID plus gabapentin 300 mg BID, showed that both groups had a reduction in the severity of symptoms that was higher in the gabapentin group, although without statistical significance [ 86 ].…”

Section: Current Treatment Options For Fdmentioning

confidence: 99%

Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review

Chaves

Pita

Libânio

et al. 2022

GE Port J Gastroenterol

View full text Add to dashboard Cite

Dyspepsia incorporates a set of symptoms originating from the gastroduodenal region, frequently encountered in the adult population in the Western world. Most patients with symptoms compatible with dyspepsia eventually end up, in the absence of a potential organic cause, being diagnosed with functional dyspepsia. Many have been the new insights in the pathophysiology behind functional dyspeptic symptoms, namely, hypersensitivity to acid, duodenal eosinophilia, and altered gastric emptying, among others. Since these discoveries, new therapies have been proposed. Even so, an established mechanism for functional dyspepsia is not yet a reality, which makes its treatment a clinical challenge. In this paper, we review some of the possible approaches to treatment, both well established and some new therapeutic targets. Recommendations about dose and time of use are also made.

show abstract

Gabapentin Improves Symptoms of Functional Dyspepsia in a Retrospective, Open-label Cohort Study

Cited by 13 publications

References 11 publications

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

A Practical 5-Step Approach to Nausea and Vomiting

Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review

Contact Info

Product

Resources

About